Sortilin as a new membrane inhibitor of EGFR trafficking for overcoming resistance to EGFR inhibitors in non-small cell lung cancer

被引：5
|
作者：
Li, Qianping [1 ,2 ]
Ma, Weijie [2 ]
Li, Tianhong [2 ,3 ]
机构：
[1] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Cardiothorac Surg, Shanghai 200233, Peoples R China
[2] Univ Calif Davis, Comprehens Canc Ctr, Dept Internal Med, Div Hematol Oncol, Sacramento, CA 95817 USA
[3] Vet Affairs Northern Calif Hlth Care Syst, Mather, CA USA
来源：
JOURNAL OF THORACIC DISEASE | 2018年 / 10卷
关键词：
GROWTH-FACTOR RECEPTOR; NF-KAPPA-B; ACTIVATION; THIOREDOXIN; PHOSPHATASE; LINE;
D O I：
10.21037/jtd.2018.08.25
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：S3186 / S3191
页数：6
相关论文
共 50 条
  • [1] The Role of Irreversible EGFR Inhibitors in the Treatment of Non-Small Cell Lung Cancer: Overcoming Resistance to Reversible EGFR Inhibitors
    Belani, Chandra P.
    [J]. CANCER INVESTIGATION, 2010, 28 (04) : 413 - 423
  • [2] Overcoming resistance to EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer
    Sierra, J. Rafael
    Chang, Anderson
    Moffat, Jason
    Neel, Benjamin G.
    Tsao, Ming-Sound
    [J]. CANCER RESEARCH, 2012, 72
  • [3] Overcoming resistance to EGFR-Tyrosine Kinase Inhibitor therapy in non-small cell lung cancer
    Sierra, Rafael
    Chang, Anderson
    Moffat, Jason
    Neel, Benjamin G.
    Tsao, Ming-Sound
    [J]. CLINICAL CANCER RESEARCH, 2012, 18 (03)
  • [4] Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer
    Park, Silvia
    Langley, Emma
    Sun, Jong-Mu
    Lockton, Steve
    Ahn, Jin Seok
    Jain, Anjali
    Park, Keunchil
    Singh, Sharat
    Kim, Phillip
    Ahn, Myung-Ju
    [J]. ONCOTARGET, 2015, 6 (31) : 30929 - 30938
  • [5] Drug Resistance to EGFR Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer
    Shien, Kazuhiko
    Yamamoto, Hiromasa
    Soh, Junichi
    Miyoshi, Shinichiro
    Toyooka, Shinichi
    [J]. ACTA MEDICA OKAYAMA, 2014, 68 (04) : 191 - 200
  • [6] Identification of resistance mechanisms to EGFR inhibitors in non-small cell lung cancer cells
    de Bruin, E. C.
    Cowell, C. F.
    Howell, M.
    Downward, J.
    [J]. EJC SUPPLEMENTS, 2010, 8 (05): : 57 - 58
  • [7] EGFR mutation heterogeneity and mixed response to EGFR tyrosine kinase inhibitors of non small cell lung cancer: a clue to overcoming resistance
    Remon, Jordi
    Majem, Margarita
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2013, 2 (06) : 445 - 448
  • [8] Mechanisms of resistance to reversible inhibitors of EGFR tyrosine kinase in non-small cell lung cancer
    Krawczyk, Pawel
    Mlak, Radoslaw
    Powrozek, Tomasz
    Nicos, Marcin
    Kowalski, Dariusz M.
    Wojas-Krawczyk, Kamila
    Milanowski, Janusz
    [J]. WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2012, 16 (05): : 401 - 406
  • [9] Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives
    Tomasello, Chiara
    Baldessari, Cinzia
    Napolitano, Martina
    Orsi, Giulia
    Grizzi, Giulia
    Bertolini, Federica
    Barbieri, Fausto
    Cascinu, Stefano
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2018, 123 : 149 - 161
  • [10] Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer
    Li, Yufeng
    Mao, Tianyu
    Wang, Jing
    Zheng, Hongrui
    Hu, Ziyi
    Cao, Pingping
    Yang, Suisui
    Zhu, Lingyun
    Guo, Shunyao
    Zhao, Xinfei
    Tian, Yue
    Shen, Hua
    Lin, Fan
    [J]. CELL COMMUNICATION AND SIGNALING, 2023, 21 (01)
12345